AR129182A1 - Proteínas de unión al antígeno - Google Patents
Proteínas de unión al antígenoInfo
- Publication number
- AR129182A1 AR129182A1 ARP230101043A ARP230101043A AR129182A1 AR 129182 A1 AR129182 A1 AR 129182A1 AR P230101043 A ARP230101043 A AR P230101043A AR P230101043 A ARP230101043 A AR P230101043A AR 129182 A1 AR129182 A1 AR 129182A1
- Authority
- AR
- Argentina
- Prior art keywords
- ulbp6
- seq
- nos
- binding protein
- cancer
- Prior art date
Links
- 102000025171 antigen binding proteins Human genes 0.000 title 1
- 108091000831 antigen binding proteins Proteins 0.000 title 1
- 101100101727 Homo sapiens RAET1L gene Proteins 0.000 abstract 11
- 102100040013 UL16-binding protein 6 Human genes 0.000 abstract 11
- 102000023732 binding proteins Human genes 0.000 abstract 8
- 108091008324 binding proteins Proteins 0.000 abstract 8
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 abstract 2
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 206010004146 Basal cell carcinoma Diseases 0.000 abstract 1
- 206010005003 Bladder cancer Diseases 0.000 abstract 1
- 206010008342 Cervix carcinoma Diseases 0.000 abstract 1
- 206010009944 Colon cancer Diseases 0.000 abstract 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 abstract 1
- 101000607316 Homo sapiens UL-16 binding protein 5 Proteins 0.000 abstract 1
- 101000607320 Homo sapiens UL16-binding protein 2 Proteins 0.000 abstract 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 abstract 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 abstract 1
- 102100040010 UL-16 binding protein 5 Human genes 0.000 abstract 1
- 102100039989 UL16-binding protein 2 Human genes 0.000 abstract 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 abstract 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 201000010881 cervical cancer Diseases 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 208000005017 glioblastoma Diseases 0.000 abstract 1
- 201000010536 head and neck cancer Diseases 0.000 abstract 1
- 208000014829 head and neck neoplasm Diseases 0.000 abstract 1
- 230000003993 interaction Effects 0.000 abstract 1
- 201000005202 lung cancer Diseases 0.000 abstract 1
- 208000020816 lung neoplasm Diseases 0.000 abstract 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000012986 modification Methods 0.000 abstract 1
- 230000004048 modification Effects 0.000 abstract 1
- 201000002528 pancreatic cancer Diseases 0.000 abstract 1
- 208000008443 pancreatic carcinoma Diseases 0.000 abstract 1
- 201000005112 urinary bladder cancer Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente descripción se relaciona con una proteína de unión a ULBP6 que inhibe la interacción entre ULBP6 y NKG2D, y métodos para tratar el cáncer con dicha proteína de unión a ULBP6. Reivindicación 1: Una proteína de unión a ULBP6 que comprende: a) (i) una cualquiera o una combinación de CDR seleccionadas de CDRH1, CDRH2, CDRH3 de las sec. con núms. de ident.: 16 - 19, y/o CDRL1, CDRL2, CDRL3 de las sec. con núms. de ident.: 26 - 29; o (ii) una variante de CDR de (i) en donde la variante tiene 1, 2, o 3 modificaciones de aminoácidos; o b) una región VH que comprende una secuencia al menos 80% idéntica a la secuencia de una cualquiera de las sec. con núms. de ident.: 21 - 24; y/o una región VL que comprende una secuencia al menos 80 % idéntica a la secuencia de una cualquiera de las sec. con núms. de ident.: 31 - 34. Reivindicación 2: La proteína de unión a ULBP6 de acuerdo con la reivindicación 1, en donde la CDR de a) (i) se selecciona del grupo que consiste en: CDRH1 de las sec. con núms. de ident.: 36, 39, 42 o 45; CDRH2 de las sec. con núms. de ident.: 37, 40, 43 o 46; CDRH3 de las sec. con núms. de ident.: 38, 41, 44 o 47; CDRL1 de las sec. con núms. de ident.: 51, 54, 57 o 60; CDRL2 de las sec. con núms. de ident.: 52, 55, 58 o 61; y CDRL3 de las sec. con núms. de ident.: 53, 56, 59 o 62. Reivindicación 7: Una proteína de unión a ULBP6 que se une a ULBP6 y ULBP2 con una KD menor que o igual a 1 nM y se une a ULBP5 con una KD mayor que o igual a 1 nM. Reivindicación 11: La proteína de unión a ULBP6 de acuerdo con la reivindicación 10, en donde el anticuerpo o un fragmento de unión al antígeno de este inhibe la unión de ULBP6 soluble a NKG2D. Reivindicación 30: La proteína de unión a ULBP6 de la reivindicación 29, en donde el cáncer es cáncer de cabeza y cuello, cáncer de cuello uterino, cáncer de vejiga, cáncer de pulmón, cáncer colorrectal, cáncer de páncreas o glioblastoma. Reivindicación 31: Una proteína de unión a ULBP6 para usar en el tratamiento del carcinoma de células basales.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263336336P | 2022-04-29 | 2022-04-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR129182A1 true AR129182A1 (es) | 2024-07-24 |
Family
ID=86604349
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP230101043A AR129182A1 (es) | 2022-04-29 | 2023-04-28 | Proteínas de unión al antígeno |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US12060426B2 (es) |
| AR (1) | AR129182A1 (es) |
| TW (1) | TW202342524A (es) |
| WO (1) | WO2023212304A1 (es) |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4666884A (en) | 1984-04-10 | 1987-05-19 | New England Deaconess Hospital | Method of inhibiting binding of von Willebrand factor to human platelets and inducing interaction of platelets with vessel walls |
| AU600575B2 (en) | 1987-03-18 | 1990-08-16 | Sb2, Inc. | Altered antibodies |
| WO1991014438A1 (en) | 1990-03-20 | 1991-10-03 | The Trustees Of Columbia University In The City Of New York | Chimeric antibodies with receptor binding ligands in place of their constant region |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US5747035A (en) | 1995-04-14 | 1998-05-05 | Genentech, Inc. | Polypeptides with increased half-life for use in treating disorders involving the LFA-1 receptor |
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| WO1997043316A1 (en) | 1996-05-10 | 1997-11-20 | Beth Israel Deaconess Medical Center, Inc. | Physiologically active molecules with extended half-lives and methods of using same |
| PL199659B1 (pl) | 1998-02-25 | 2008-10-31 | Merck Patent Gmbh | Białko fuzyjne przeciwciała hu-KS IL2, cząsteczka DNA kodująca białko fuzyjne przeciwciała hu-KS IL2 i sposób wytwarzania białka fuzyjnego przeciwciała hu-KS IL2 |
| US20020142374A1 (en) | 1998-08-17 | 2002-10-03 | Michael Gallo | Generation of modified molecules with increased serum half-lives |
| IL127127A0 (en) | 1998-11-18 | 1999-09-22 | Peptor Ltd | Small functional units of antibody heavy chain variable regions |
| PL209392B1 (pl) | 1999-01-15 | 2011-08-31 | Genentech Inc | Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała |
| EP2278003B2 (en) | 1999-04-09 | 2020-08-05 | Kyowa Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
| WO2001029246A1 (fr) | 1999-10-19 | 2001-04-26 | Kyowa Hakko Kogyo Co., Ltd. | Procede de production d'un polypeptide |
| US6374470B1 (en) | 2000-10-06 | 2002-04-23 | Milliken & Company | Face plate for spun-like textured yarn |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| DE60143544D1 (de) | 2000-12-12 | 2011-01-05 | Medimmune Llc | Moleküle mit längeren halbwertszeiten, zusammensetzungen und deren verwendung |
| PL217751B1 (pl) | 2001-08-03 | 2014-08-29 | Glycart Biotechnology Ag | Zastosowanie glikomodyfikowanego przeciwciała do wytwarzania kompozycji farmaceutycznej do leczenia choroby wybranej z grupy składającej się z nowotworu, małopłytkowości autoimmunologicznej w przewlekłej chorobie przeszczep przeciwko gospodarzowi i immunozależnej nabytej aplazji czysto czerwonokrwinkowej |
| EP1391213A1 (en) | 2002-08-21 | 2004-02-25 | Boehringer Ingelheim International GmbH | Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents |
| EP1776385A1 (en) | 2004-07-21 | 2007-04-25 | Glycofi, Inc. | Immunoglobulins comprising predominantly a glcnac2man3glcnac2 glycoform |
| US7923538B2 (en) | 2005-07-22 | 2011-04-12 | Kyowa Hakko Kirin Co., Ltd | Recombinant antibody composition |
| WO2007011041A1 (ja) | 2005-07-22 | 2007-01-25 | Kyowa Hakko Kogyo Co., Ltd. | 遺伝子組換え抗体組成物 |
| KR101791430B1 (ko) | 2009-11-30 | 2017-10-30 | 얀센 바이오테크 인코포레이티드 | 이펙터 기능이 제거된 항체 Ｆｃ 돌연변이체 |
| KR101614195B1 (ko) | 2011-03-29 | 2016-04-20 | 로슈 글리카트 아게 | 항체 Fc 변이체 |
| WO2014140884A2 (en) * | 2013-03-15 | 2014-09-18 | Novelogics Biotechnology, Inc. | Methods and devices for removal of immunosuppressive ligands |
-
2023
- 2023-04-28 AR ARP230101043A patent/AR129182A1/es unknown
- 2023-04-28 WO PCT/US2023/020381 patent/WO2023212304A1/en unknown
- 2023-04-28 US US18/309,272 patent/US12060426B2/en active Active
- 2023-05-01 TW TW112116171A patent/TW202342524A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023212304A1 (en) | 2023-11-02 |
| TW202342524A (zh) | 2023-11-01 |
| US20230348604A1 (en) | 2023-11-02 |
| US12060426B2 (en) | 2024-08-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI3484915T3 (fi) | Uusia zikavirusepitooppeihin spesifisesti sitoutuvia vasta-aineita ja niiden käyttöjä | |
| RU2019118359A (ru) | Антитело к cd73 человека | |
| RU2588467C3 (ru) | Стабильные и растворимые антитела, ингибирующие vegf | |
| IL259940B2 (en) | A method for treating or improving metabolic disorders using gastric inhibitory peptide receptor binding proteins in combination with glucagon-like peptide 1 agonists | |
| JP2020515508A5 (es) | ||
| JP2018108081A5 (es) | ||
| RU2009120052A (ru) | Композиции и способы связывания сфингозин-1-фосфата | |
| JP2020500538A5 (es) | ||
| PE20231958A1 (es) | Moleculas de union a pd-1 y metodos de uso de las mismas | |
| NZ623347A (en) | Novel anti-dr5 antibody | |
| RU2017104815A (ru) | Молекулы со специфичностью в отношении cd79 и cd22 | |
| AR066164A1 (es) | Proteinas humanas de union a antigenos del factor estimulante de colonias de megacariocitos-macrofagos(gm-csf) | |
| PE20121579A1 (es) | Proteinas de enlace al antigeno il-23 humanas | |
| CL2013003140A1 (es) | Un anticuerpo monoclonal humano aislado o fragmento de union a antigeno del mismo que se une a masp-2 humana; molecula de acido nucleico, casette de expresion, celula que la expresa, metodo de produccion, composicion que la contiene, articulo que lo contiene. | |
| RU2011105062A (ru) | Нейтрализующие антитела против вируса гриппа а и их использование | |
| HRP20191590T1 (hr) | Protutijela za bubrežni antigen 1 i njihov fragment koji veže antigen | |
| PE20221865A1 (es) | Anticuerpos contra el virus de la fiebre amarilla y metodos de su generacion y uso | |
| RU2016137256A (ru) | АНТИТЕЛА К ФАКТОРУ КОМПЛЕМЕНТА Bb | |
| JP2023134705A5 (es) | ||
| PE20221151A1 (es) | Anticuerpos anti-cd96 y sus metodos de uso | |
| JP2018512124A5 (es) | ||
| CO2022013885A2 (es) | Anticuerpo biespecífico | |
| JP2021501579A5 (es) | ||
| AR129182A1 (es) | Proteínas de unión al antígeno | |
| JP2017511152A5 (es) |